Clinical trials: Desmoid-Type Fibromatosis
Desmoid Tumor, Desmoid Fibromatosis
A Prospective Clinical Study on the Safety and Efficacy of Radiofrequency Ablation for the Treatment of Patients With Desmoid Tumors
This is a prospective study on the safety and effectiveness of radiofrequency ablation in patients with desmoid tumors. In the study group, all patients after radiofrequency ablation of the tumor after 1 month will be evaluated…
- Conditions
- Desmoid Tumor, Desmoid Fibromatosis, Desmoid
- Trial name
- RFAdesmoid (NCT06355921)
- Testing
- radiofrequency ablation
- Where
- Russia
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Blokhin's Russian Cancer Research Center
Desmoid Tumor, Quality of Life
Burden of Disease and Living Situation in Desmoid Patients
The main aim of the study is to assess the situation and quality of life of desmoid patients. Impaired areas of quality of life and the associated factors are to be identified.
- Trial name
- PROSa Desmoid (NCT06258421)
- Testing
- No Intervention
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Technische Universität Dresden
Soft Tissue Sarcoma, Desmoid Tumors
HIFU Ablation of Soft Tissue Sarcoma
Around 3,300 people are diagnosed with soft tissue sarcoma (STS) each year in the UK, and a significant proportion of STS diagnoses are in people aged under 30 years.
- Trial name
- SarcAblate (NCT05111964)
- Testing
- High Intensity Focused Ultrasound Ablation, Tumour Biopsy and Venous Blood Tests
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Oxford University Hospitals NHS Trust
Desmoid Tumor
Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects of imatinib mesylate and to see how well it works…
- Trial name
- NCT00287846
- Testing
- imatinib mesylate
- Where
- 23 sites in France
- Volunteers
- 40 people
- Sponsor
- UNICANCER
Desmoid
Clinical Study of Anlotinib Combined With Chemotherapy in the Treatment of Unresectable Advanced Desmoid Tumor
Thirty patients with desmoid tumors (invasive fibromatosis) will be recruited in the Department of Bone and Soft Tissue, Henan Cancer Hospital.
- Trial name
- NCT05490667
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Cancer Hospital
Fibromatosis
A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)
Aggressive fibromatosis (AF, also known as desmoid tumor) is a fibroproliferative neoplasm that typically arises in the abdomen but can develop at other anatomic sites, most commonly in the extremities.
- Trial name
- NCT02495519
- Testing
- Imatinib
- Where
- South Korea
- Volunteers
- 21 people
- Sponsor
- Yonsei University
Desmoid Tumor
A Study in Adults With Desmoid Tumors
This is an open-label, multicenter, single-arm phase 2 clinical study designed to evaluate the efficacy, safety, tolerability, patient-reported outcomes (PROs), pharmacokinetics (PK), anti-drug antibody (ADA) and pharmacodynamics…
- Trial name
- NCT07541430
- Testing
- ES014
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Elpiscience (Suzhou) Biopharma, Ltd.
Desmoid Tumor, NOTCH Gene Mutation Positive Tumors
Individual Patient Compassionate Use of Nirogacestat
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.
- Trial name
- NCT05041036
- Testing
- Nirogacestat (Gamma Secretase Inhibitor)
- Where
- 2 sites in United States, Germany
- Sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Desmoid Tumor, Aggressive Fibromatosis
Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
This study evaluates nirogacestat (PF-03084014) in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). In the double-blind phase, half of the participants will receive nirogacestat while the other half will receive…
- Trial name
- DeFi (NCT03785964)
- Testing
- Nirogacestat oral tablet
- Where
- 52 sites in United States, Belgium and 5 more
- Volunteers
- 142 people
- Sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Hernia, Ventral, Intestinal Fistula
RCT of Two Noncrosslinked Porcine Acellular Dermal Matrices in Ab Wall Reconstruction
The purpose of the study is to compare the clinical outcomes of two commonly used, FDA-approved biologic meshes in hernia repair and abdominal wall reconstruction (Strattice and XenMatrix).
- Conditions
- Hernia, Ventral, Intestinal Fistula, Fibromatosis, Abdominal
- Trial name
- NCT02228889
- Testing
- Abdominal wall reconstruction with Strattice, Assess pain intensity at last office visit preoperatively, Assess pain interference at last office visit preoperatively
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Jeffrey Janis
Desmoid Fibromatosis
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
This randomized phase III trial compares the effects, good and/or bad, of sorafenib tosylate in treating patients with desmoid tumors or aggressive fibromatosis.
- Trial name
- NCT02066181
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Sorafenib Tosylate
- Where
- 150 sites in United States, Canada
- Volunteers
- 87 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma
Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma
This is a Phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin as first, second or third line therapy for advanced sarcoma, including desmoid tumor and chordoma.
- Trial name
- TNT (NCT03886311)
- Testing
- Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC], Nivolumab IV Soln 100 MG/10ML, Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
Familial Adenomatous Polyposis (FAP)
A Safety Study of ST316 in Participants With Familial Adenomatous Polyposis (FAP).
This is a Phase 1b, open- label, dose-optimization study evaluating ST316 in adult participants with familial adenomatous polyposis (FAP) who have undergone colectomy and have recurrent polyps.
- Trial name
- FAP (NCT07729371)
- Testing
- ST316 IV
- Volunteers
- 40 people
- Sponsor
- Sapience Therapeutics
Familial Adenomatous Polyposis (FAP), Attenuated Familial Adenomatous Polyposis (AFAP)
Familial Adenomatous Poliposys Italian Network (Rete Italiana Poliposi Adenomatosa Familiare)
RIPAF (Rete Italiana Poliposi Adenomatosa Familiare) is a national, multicenter observational registry designed to establish a coordinated Italian network for the management of Familial Adenomatous Polyposis (FAP) and related…
- Conditions
- Familial Adenomatous Polyposis (FAP), Attenuated Familial Adenomatous Polyposis (AFAP), MUTYH-Associated Polyposis (MAP), Non-APC/MUTYH Associated Polyposis (NAMP)
- Trial name
- RIPAF (NCT07461246)
- Where
- Italy
- Volunteers
- 1,500 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Desmoid Tumor
A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor
This is a phase I/II, open-label, non-randomized, multicentre study to evaluate the clinical activity of vactosertib plus imatinib in desmoid tumor.
- Trial name
- NCT03802084
- Testing
- vactosertib/imatinib combination
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Hyo Song Kim
Desmoid
Arterial Chemoembolization for the Treatment of Desmoid Fibromatosis
Desmoid fibromatoses are rare (1-2 cases/million per year) and locally aggressive mesenchymal tumors. For asymptomatic disease, current guidelines suggest an initial period of active surveillance.
- Trial name
- Embodesmo (NCT06268457)
- Testing
- Chemoembolization with Doxorubicin
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Istituto Ortopedico Rizzoli